Antengene (HKG:6996) will establish a dedicated artificial intelligence department by increasing its investment in AI-driven drug discovery and AI-focused R&D efforts.

The initiative includes deploying DeepSeek to expedite the development of its next-generation proprietary T-cell engager (TCE) pipeline, which features a steric hindrance-masking technology.

The drugmaker plans to leverage targeted algorithms and AI-driven data mining to perform cross-database, multi-omics analyses for drug discovery and development, a Wednesday bourse filing said.